2020 Epilepsy Research Benchmarks

Benchmark Area III

Benchmark 3 – Improve treatment options for controlling seizures and epilepsy-related conditions without side effects.

• For new genes/pathways that have been figured out for monogenetic conditions, promote or support gene modifying solutions.

• Understand how dysfunctional networks allow propagation of seizures

• Explore how intervention in a network rather than on a seizure focus could eliminate seizures or improve seizure outcomes.

• Development and validation of patient-reported non-seizure outcome measures such quality of life and important co-morbidities that are appropriate for more severe epilepsy populations.

• Conduct longitudinal analysis of functional reorganization after epilepsy surgery, especially in (but not limited to) developing brains in children (connectome).

• Establish comparative effectiveness of existing medicines for the epilepsies, i.e., how do we learn how to give the right drug to the right person at the right time?

• Conduct longitudinal natural history studies of rare epilepsy syndromes

• Assess outcomes of new therapies and surgery in broader populations of people than are enrolled in randomized clinical trials (e.g., generalizability in assessment of outcomes of new therapies), including expanding to other languages and underrepresented populations

• Developing better tools to visualize seizure propagation in humans

• Seek to better understand biomarkers of treatment response, adverse effects and SUDEP

• Explore the potential role of weather/barometric pressure as a novel seizure trigger

Which Benchmark Area (I-IV) does your submission address? Area III

Which Research Benchmark component does your submission address (A, B, C, D, E, F)? A

In addition to the Benchmark feedback, does your feedback apply to additional research areas (A, B, C, D, E, F) and if so, please elaborate?

B, C, D, E




0 votes
Benchmark Feedback
Idea No. 220